BridgeBio Pharma Inc
NASDAQ:BBIO

Watchlist Manager
BridgeBio Pharma Inc Logo
BridgeBio Pharma Inc
NASDAQ:BBIO
Watchlist
Price: 77.87 USD -2.55% Market Closed
Market Cap: $15B

Net Margin

-225.3%
Current
Improving
by 1 994.7%
vs 3-y average of -2 220%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-225.3%
=
Net Income
$-797.1m
/
Revenue
$353.8m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-225.3%
=
Net Income
$-797.1m
/
Revenue
$353.8m

Peer Comparison

Country Company Market Cap Net
Margin
US
BridgeBio Pharma Inc
NASDAQ:BBIO
15B USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
387.5B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
185.5B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
168.8B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
119B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.3B USD
Loading...
AU
CSL Ltd
ASX:CSL
87B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.2B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.2B USD
Loading...

Market Distribution

Lower than 89% of companies in the United States of America
Percentile
11th
Based on 15 072 companies
11th percentile
-225.3%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

BridgeBio Pharma Inc
Glance View

Market Cap
15B USD
Industry
Biotechnology

BridgeBio Pharma Inc. stands as a compelling figure in the biotechnology sector, driven by its mission to address and rectify genetic diseases at their root. Formed with the belief that breakthrough medicines for genetic disorders could be developed with unprecedented speed and precision, the company focuses on identifying clinically validated genetic pathways. By collaborating with leading researchers and utilizing sophisticated drug development platforms, BridgeBio seeks to rapidly translate genetic insights into medical innovations. The company's distinct approach concentrates on single-gene disorders across various therapeutic areas including oncology, cardiology, dermatology, and neurology. The financial workings of BridgeBio Pharma revolve around its robust pipeline of targeted therapies. Essentially, its revenue model is anchored in developing investigational therapies that hold the potential for lucrative partnerships and licensing deals with larger pharmaceutical entities. As these therapies progress through clinical stages, their valuation—and hence the potential for revenue—significantly increases. BridgeBio also leverages a strategy of creating subsidiary companies for each drug in its pipeline, promoting both focus and accountability. This organizational structure enables efficient capital allocation and innovation while also opening up opportunities for public market offerings and strategic exits, thereby driving the financial engine of BridgeBio.

BBIO Intrinsic Value
HIDDEN
Show
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-225.3%
=
Net Income
$-797.1m
/
Revenue
$353.8m
What is BridgeBio Pharma Inc's current Net Margin?

The current Net Margin for BridgeBio Pharma Inc is -225.3%, which is above its 3-year median of -2 220%.

How has Net Margin changed over time?

Over the last 3 years, BridgeBio Pharma Inc’s Net Margin has increased from -553.5% to -225.3%. During this period, it reached a low of -10 087.9% on Jun 30, 2023 and a high of -201.5% on Sep 30, 2024.

Back to Top